检索结果-南通市图书馆

Cancer Communications 2021年第11期41卷 1232-1233页

作者： Sang Eun Yoon won seog kim Division of Hematology-oncology Department of MedicineSamsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Korea

Extranodal naturalkiller/T-cell lymphoma(ENKTL)is a distinct subtype of non-Hodgkin lymphoma(NHL)with aggressive clinical course and is closely associated with Epstein Barr virus(EBV)infection[1].Due to the unique feature that majority of ENKTL patients have involvement of the upper aerodigestive tract(UADT),the commonly used international prognostic index(IPI)system for NHL is not applicable for ENKTL as most of the patients would be divided into the low-risk group[2].Thus,an optimal prognostic system for ENKTL remains *** models particularly constructed for ENKTL have been reported and several potential risk factors such as regional lymph node involvement,nasal type disease,primary tumor invasiveness,and EBV-DNA,were identified as independent prognostic factors[3–5].

关键词： involvement killer lymphoma

Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第36期19卷 6062-6068页

作者： Sang-won kim Do Hoon Lim Yong Chan Ahn won seog kim Seok Jin kim Young Hyeh Ko Kyoung-Mee kim Department of Radiation Oncology Samsung Medical Center Sungkyunkwan University School of Medicine Division of Hematology and Oncology Department of Medicine Samsung Medical CenterSungkyunkwan University School of Medicine Department of Pathology Samsung Medical Center Sungkyunkwan University School of Medicine

AIM:To evaluate the clinical outcomes of radiation therapy(RT)for early-stage gastric mucosa-associated lymphoid tissue lymphoma(MALToma).METHODS:The records of 64 patients treated between 1998 and 2011 were analyzed *** Helicobacter pylori(***)-positive patients(n=31),chemotherapy or *** eradication therapy was the initial *** patients with failure after *** eradication,RT was *** *** patients(n=33),chemotherapy or RT was the first-line *** median RT dose was *** target volume included the entire stomach andthe perigastric lymph node ***:All of the patients completed RT without interruption and showed complete remission on endoscopic biopsy after *** a median follow-up period of 39 mo,the 5-year local control rate was 89%.Salvage therapy was successful in all relapsed *** malignancies developed in three *** 5-year overall survival rate was 94%.No patient presented symptoms of moderate-to-severe treatmentrelated toxicities during or after ***:Radiotherapy results in favorable clinical outcomes in patients with early-stage gastric MALToma who experience failure of *** eradication therapy and those who are *** negative.

关键词： Gastric mucosa-associated lymphoid tissue lymphoma Radiation therapy Treatment response

New insights on Epstein-Barr virus-induced lymphomagenesis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Science Bulletin 2024年第22期69卷 3478-3479页

作者： Sang Eun Yoon won seog kim Division of Hematology-Oncology Department of MedicineSamsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea

Natural killer(NK)/T-cell lymphoma(NKTCL)is an aggressive extranodal lymphoma prevalent in East Asia and Latin America and characterized by invariable infection with Epstein-Barr virus(EBV)[1].Tumor positivity for EBV titer in in situ hybridization is an important biomarker for diagnosis,and circulation of EBV DNA in blood derived from necrotic or apoptotic tumor cells is strongly linked to treatment and survival outcomes[1].Xiong et al.

关键词： lymphoma diagnosis al.

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2021年第3期41卷 275-278页

作者： Jun Ho Yi Seok Jin kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok Hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung kim Dae Sik kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung kim won seog kim Division of Hematology-Oncology Department of MedicineChung-Ang UniversityDongjak-guSeoul 06973Korea Division of Hematology and Oncology Department of MedicineSamsung Medical Center Sungkyunkwan University School of MedicineGangnam-guSeoul 06351Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Korea National Health Insurance Corporation Ilsan Hospital Ilsandong-guGoyang 10444Korea Department of Hemato-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolHwasunGwangju 58128Korea Department of Hematology and Oncology Ulsan University HospitalUniversity of Ulsan College of MedicineDong-guUlsan 44033Korea Department of Internal Medicine Yonsei University Wonju College of MedicineGangwon-DoWonju 26426Korea Department of Internal Medicine National Cancer CenterGoyang-si Gyeonggi-doGoyang 10408Korea Department of Internal Medicine Seoul National University Bundang HospitalBundang-guSeongnam 13620Korea Department of Internal Medicine ChungBuk National University HospitalChungbukCheongju 28644Korea Department of Internal Medicine Jeju National University HospitalJeju National University School of MedicineJeju 63241Korea Department of Hematology-Oncology Wonkwang University HospitalIksan-daeroIksan 54538Korea Department of Internal Medicine Jeonbuk National University Medical SchoolJeollabuk-doJeonju 54907Korea Division of Hematology-Oncology Department of Internal MedicineSoonchunhyang University College of MedicineBucheon HospitalWonmi-guBucheon 14584Korea Division of Hematology-Oncology Department of Internal MedicineKorea University Guro HospitalGuro-guSeoul 08308Korea Division of Hematology-Oncology Department of Internal MedicineDong-A University College of MedicineSeo-guBusan 49201Korea Department of Internal Medicine Division of Hematology-Oncology Catholic University of DaeguDaegu 42472Korea Division of Hematology-Oncology Department of Internal MedicineHallym U

Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease.

关键词： patients relapse lymphoma

Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 526-535页

作者： Sung Yong Oh won seog kim Jin Seok kim Seok Jin kim Dok Hyun Yoon Deok-Hwan Yang won Sik Lee Hyo Jung kim Ho-Young Yhim Seong Hyun Jeong Jong Ho won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-won Lee Jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Republic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology-Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology-Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology-Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology-Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment ***,extending the period of remission in MZL patients remains an essential *** multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further ***:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV ***(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week *** patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 *** primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment ***:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance ***(33%)patients had nodal *** R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,*** a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of *** LDH and the presence of B symptoms were found to be significant prognostic fac

关键词： Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine Maintenance Multicenter Open label Survival

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh won seog kim Jin Seok kim Seok Jin kim Dok Hyun Yoon Deok‑Hwan Yang won Sik Lee Hyo Jung kim Ho‑Young Yhim Seong Hyun Jeong Jong Ho won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑won Lee Jae Hoon Lee Ho Sup Lee Ho‑Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存

Portable and Efficient Implementation of CRYSTALS-Kyber Based on WebAssembly

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Computer Systems Science & Engineering 2023年第8期46卷 2091-2107页

作者： seog Chung Seo HeeSeok kim Department of Financial Information Security Kookmin UniversitySeoul02707Korea Department of Cyber Security College of Science and TechnologyKorea UniversitySejong30019Korea

With the rapid development of quantum computers capable of realizing Shor’s algorithm,existing public key-based algorithms face a significant security ***-Kyber has been selected as the only key encapsulation mechanism(KEM)algorithm in the National Institute of Standards and Technology(NIST)Post-Quantum Cryptography(PQC)*** this study,we present a portable and efficient implementation of a Crystals-Kyber post-quantum KEM based on WebAssembly(Wasm),a recently released portable execution framework for high-performance web *** now,most Kyber implementations have been developed with native programming languages such as C and *** there are a few previous Kyber implementations based on JavaScript for portability,their performance is significantly lower than that of implementations based on native programming ***,it is necessary to develop a portable and efficient Kyber implementation to secure web applications in the quantum computing *** Kyber software is based on JavaScript and Wasm to provide portability and efficiency while ensuring quantum ***,the overall software is written in JavaScript,and the performance core parts(secure hash algorithm-3-based operations and polynomial multiplication)are written in ***,we parallelize the number theoretic transform(NTT)-based polynomial multiplication using single instruction multiple data(SIMD)functionality,which is available in *** three steps in the NTT-based polynomial multiplication have been parallelized with Wasm SIMD intrinsic *** software outperforms the latest reference implementation of Kyber developed in JavaScript by×4.02(resp.×4.32 and×4.1),×3.42(resp.×3.52 and×3.44),and×3.41(resp.×3.44 and×3.38)in terms of key generation,encapsulation,and decapsulation on Google Chrome(***,and Microsoft Edge).As far as we know,this is the first software implementation of Kyber with Wasm technology in the web enviro

关键词： Crystals-kyber post-quantum cryptosystem(PQC) javascript WebAssembly SIMD web application internet of things(IoT) edge computing

Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第41期19卷 7078-7088页

作者： Jae Yun Lim Sun Och Yoon So-Young Seol Soon won Hong Jong won kim Seung Ho Choi Ju-seog Lee Jae Yong Cho Department of Medical Oncology Gangnam Severance Cancer HospitalYonsei University College of MedicineSeoul 135-720South Korea Department of Systems Biology Division of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHoustonTX 77030United States Department of Pathology Gangnam Severance Cancer HospitalYonsei University College of Medicine 135-720SeoulSouth Korea Department of Surgery Gangnam Severance Cancer HospitalYonsei University College of MedicineSeoul 135-720South Korea

AIM:To identify molecular biologic differences between two gastric adenocarcinoma subgroups presenting different prognoses through the analysis of microRNA and protein ***:Array technologies were used to generate1146 microRNAs and 124 proteins expression profiles of samples from 60 patients with gastric *** the integrative analysis,we used established mRNA expression data published in our previous *** mRNA expression levels were acquired from microarray data for 60 identical gastric cancer *** gastric adenocarcinoma subgroups with distinct mRNA expression profiles presented distinctly different *** and protein expression patterns were compared between gastric cancer tissue and normal gastric tissue and between two different prognostic *** expressed microRNA,associated mRNA,and protein in patients with poor-prognosis gastric cancer were validated by quantitative reverse transcription polymerase chain reaction and immunochemistry in independent ***:We obtained the expression data of 1146microRNAs and 124 cancer-related *** microRNAs were aberrantly expressed in the two prognostic groups and in cancer vs non-cancer tissues(P<0.05).In the poor-prognosis group,miR-196b,miR-135b,and miR-93 were up-regulated and miR-29c*was ***-196b expression positively correlated with Homeobox A10(HOXA10)expression(r=0.726,P<0.001),which was significantly increased in poor-prognosis patients(P<0.001).Comparing gastric cancer with non-cancer tissues,46/124 proteins showed differential expression(P<0.05);COX2(P<0.001)and cyclin B1(P=0.017)were clearly overexpressed in the poor-prognosis ***:Co-activation of miR-196b and HOXA10characterized a poor-prognosis subgroup of patients with gastric *** of the biologic function of miR-196b and HOXA10 is warranted.

关键词： Gastric cancer Gene expression Microarray MicroRNA miR-196b Homeobox A10

Fabrication of Barrier Ribs for PDP by Capillary Infiltration Process and Their Sintering Behavior

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Rare Earths 2004年第Z2期22卷 98-101页

作者： Tae Jung Tang Hak Nynu Choi Chan Hyoung Kang Yong seog kim Department of Materials Science and Engineering Hongik UniversitySeoul 121-791Korea Department of Materials Science and EngineeringHongik UniversitySeoul 121-791Korea Department of Advanced Materials EngineeringKorea Polytechnic University Shihung-CityKyonggi-DoKorea Department of Materials Science and EngineeringHongik UniversitySeoul 121-791Korea

Closed-cell type barrier ribs such as meander, honeycomb, SDR, and waffle types were produced using capillary molding process. Sintering of the ribs revealed that the ribs with asymmetric geometry such as meander and SDR type became distorted severely by the sintering process, but the ribs with symmetric geometry such as honeycomb and waffle type maintained their green state morphology. After sintering, the ribs were coated with green phosphor using osmosis coating process and its luminance characteristics were evaluated. The results indicated that the luminance and its efficiency is improved by using closed-cell type ribs with the new phosphor forming technology.

关键词： PDP close celled barrier ribs sintering distortion

Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients： a phase Ⅰ/Ⅱ trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2015年第1期12卷 87-95页

作者： Soyoung Baek Yong-Man kim Sung-Bae kim Choung-Soo kim seog-Woon Kwon YongMan kim HyunSoo kim Hyunah Lee Office of Biomedical Professors Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea Department of Gynecology Asan Medical Center University of Ulsan College of Medicine Seoul Korea Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Korean Department of Urology Asan Medical Center University of Ulsan College of Medicine Seoul Korean Department of Laboratory Medicine Asan Medical Center University of Ulsan College of Medicine Seoul Korea FCB-Pharmicell Co Ltd Seoul Korea

While ovarian cancer （OvCa） responds well to surgery and conventional chemotherapy, a high recurrence rate of advanced OvCa is observed. In this phase Ⅰ/Ⅱ study, 10 OvCa patients with minimal residual disease were treated with autologous dendritic cells （DCs） and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and to characterize the antigen-specific immune alterations induced through this treatment. Approximately 4 months after initial debulking and chemotherapy, patients received two subcutaneous doses of autologous monocyte-derived DCs pulsed with autologous tumor lysate and keyhole limpet hemocyanin （KLH） at 4-week intervals. After each DC inoculation, low-dose （200 mlU） IL-2 was introduced for 14 consecutive days as an immune adjuvant. The vaccination was well tolerated. In three out of 10 patients, the inclusion status after the initial therapy showed the maintenance of complete remission （CR） after DC vaccination for 83, 80.9 and 38.2 months without disease relapse. One patient with stable disease （SD） experienced the complete disappearance of tumor after DC vaccination, and this status was maintained for 50.8 months until tumor recurrence. In two patients with partial response （PR） was not responding to DC vaccination and their disease recurred. In the three patients with disease free long-term survival, significant immune alterations were observed, including increased natural killer （NK） activity, IFN-γ-secreting T cells, immune-stimulatory cytokine secretion and reduced immune-suppressive factor secretion after DC vaccination. Thus, in patients with NED status and increased overall survival, DC vaccination induced tumor-related immunity, potentially associated with long-term clinical responses against OvCa.

关键词： dendritic cell vaccine immune response ovarian cancer phase Ⅰ/Ⅱ trial